11.49 stock price up
Change
+ 0.74 (6.88%)
Volume
7,600
Exchange
NASDAQ
3:59 PM ET on Dec 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.
4.35 stock price up
Change
+ 0.12 (2.91%)
Volume
216,339
Exchange
TASE
3:24 PM IT on Dec 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.
View all »Recent Releases

Dec 17, 2014
RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis

Dec 9, 2014
RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application for Oncology Support

Dec 2, 2014
RedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting

Investor Relations (US):

Lauren Glaser
Vice President
The Trout Group LLC
Direct: +1 646 378 2972
Cell: +1 215 740 8468
email: lglaser@troutgroup.com

Investor Relations (Israel):

Eran Gabay
Vice President & Managing Director
Financial PR and Strategic Communications
Gelbart-Kahana Investor Relations
Direct: +972 (0)3 6070 591
email: erang@gk-biz.com

General:

RedHill Biopharma Ltd.
21 Ha’arba’a St., Tel-Aviv 64739, Israel
Tel: +972 (0)3 541 3131
Fax: +972 (0)3 541 3144
email: info@redhillbio.com